Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update


ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31, 2024, and provided an overview of the Company’s progress.

Read the original post:
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Related Posts